Lorenc Z Paul, Daro-Kaftan Elizabeth
J Drugs Dermatol. 2014 Feb;13(2):191-5.
Reversal of the visible signs of facial aging with the use of injectable products as an alternative to surgery has become more popular, with nearly 5 million procedures performed in the United States in 2012. Volume augmentation products, such as hyaluronic acid (HA), calcium hydroxylapatite (CaHA), and poly-L-lactic acid (PLLA), are often used in combination with one another and with neurotoxins for facial rejuvenation because of the complementary modes of action. This article presents 2 case reports involving patientspecific combinations of 2 different HA products, injectable PLLA, and CaHA with incobotulinumtoxinA or abobotulinumtoxinA. The combination of HA, CaHA, PLLA, and neurotoxins has resulted in outstanding outcomes for many patients, with no clinical evidence of increased adverse events secondary to combination therapy.
使用可注射产品替代手术来逆转面部衰老的明显迹象已变得更加流行，2012年在美国有近500万例此类手术。诸如透明质酸（HA）、羟基磷灰石钙（CaHA）和聚左旋乳酸（PLLA）等填充产品，由于其互补的作用方式，常常相互联合使用，并与神经毒素一起用于面部年轻化。本文呈现了2例病例报告，涉及2种不同HA产品、可注射PLLA和CaHA与incobotulinumtoxinA或abobotulinumtoxinA的患者特异性组合。HA、CaHA、PLLA和神经毒素的联合使用已为许多患者带来了出色的效果，没有临床证据表明联合治疗会增加不良事件。
